


Vorinostat

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-10221 | | |
| CAS No.: | 149647-78-9 | | |
| Molecular Formula: | C ₁₄ H ₂₀ N ₂ O ₃ | | |
| Molecular Weight: | 264 | | |
| Target: | HDAC; Autophagy; Mitophagy; Filovirus; Apoptosis; HPV | | |
| Pathway: | Cell Cycle/DNA Damage; Epigenetics; Autophagy; Anti-infection; Apoptosis | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 1 year |
| | | -20°C | 6 months |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (378.79 mM)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Concentration | Mass | | |
|---------------------------|-----------------------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| | 1 mM | 3.7879 mL | 18.9394 mL | 37.8788 mL |
| | 5 mM | 0.7576 mL | 3.7879 mL | 7.5758 mL |
| | 10 mM | 0.3788 mL | 1.8939 mL | 3.7879 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 20% HP-β-CD in saline
Solubility: 3.33 mg/mL (12.61 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: ≥ 2.5 mg/mL (9.47 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.47 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution

9. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.88 mM); Clear solution

BIOLOGICAL ACTIVITY

| | | | | |
|-------------------------------------|---|-----------------------|-----------|-------|
| Description | Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID ₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis ^{[1][4]} . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification ^[7] . | | | |
| IC₅₀ & Target | HDAC1 10 nM (ID50) | HDAC3 20 nM (ID50) | HDAC2 | HDAC7 |
| | HDAC11 | Autophagy | Mitophagy | |
| In Vitro | <p>Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21 WAF1 expression and apoptosis in MES-SA cells^[1].</p> <p>Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC₂₅ values of 1 μM and 0.5 μM, respectively^[2].</p> <p>Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers apoptosis in HPV-infected, differentiated cells^[7].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> | | | |
| In Vivo | <p>Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×10^6 MES-SA cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> | | | |

PROTOCOL

| | |
|---|--|
| Cell Assay ^[1] | <p>Cell lysates are prepared by using RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), and the protein concentration is determined by Bio-Rad DC Protein Assay. Protein lysates are separated by SDS-PAGE and transferred to nitrocellulose membrane. Following antibodies and dilutions are used: rabbit anti HDAC1 (1 μg/mL); rabbit anti HDAC2 (1 μg/mL); rabbit anti HDAC3 (9 μg/mL); rabbit anti HDAC7 (3 μg/mL); mouse anti p21WAF1 (0.5 μg/mL). As secondary antibodies, the rabbit anti-mouse and swine anti-rabbit HRP-coupled antibodies at a final concentration of 1 μg/mL. An overnight incubation at 4°C is used for all primary antibodies, followed by washing and 2-hours incubation at RT with secondary antibodies. Specific protein bands are visualized by enhanced chemiluminescence assay. To demonstrate equal loading of protein samples all western blots are probed for β-tubulin.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |
| Animal Administration ^[1] | <p>Twelve weeks old male mice (n=14) are anesthetized with Isofluran and 5×10^6 MES-SA cells are injected subcutaneously into the right flank of the animal. Mice from a control group receives placebo containing 300 μL of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice receives vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat are administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size ($w^2 \times l \times 0.52$; measured by caliper) are estimated twice a week. All mice are treated for 21 days and afterwards sacrificed by cervical dislocation. Each tumor is isolated as a whole and different tumor parameters are determined. Finally, tumor slices are cryo preserved and formalin fixed (4%) for further analyses.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

CUSTOMER VALIDATION

- Protein Cell. 2023 Nov 27;pwad056.
- Mil Med Res. 2022 Sep 27;9(1):54.
- Nat Commun. 2021 Mar 3;12(1):1407.
- Nat Commun. 2017 Dec 20;8(1):2207.
- J Exp Med. 2022 Jan 3;219(1):e20210789.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. *Mol Cancer*. 2010 Mar 4;9:49.
 - [2]. Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. *PLoS One*. 2012;7(7):e40816.
 - [3]. Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc Natl Acad Sci U S A*. 1998 Mar 17;95(6):3003-7.
 - [4]. Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. *Oncogene*. 2007 Aug 13;26(37):5541-52.
 - [5]. Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. *Mol Psychiatry*. 2017 May;22(5):711-723.
 - [6]. Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. *Nat Commun*. 2017 Dec 20;8(1):2207.
 - [7]. Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. *Proc Natl Acad Sci U S A*. 2018 Nov 20;115(47):E11138-E11147.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA